RxDoctor Payments Data

Justin Case, MD

Internal Medicine · Florence, KYNPI 1609044015

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $30,440 of the $41,109 with a category attached, or 74.0%. 31 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 51.8% of the total. 2025 is the largest year on record at $22,241, more than ten times the $652 reported in 2019. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,109in general payments, 2019–2025

Across 507 payments — averaging $81.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$21K
  • AbbVie$14K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Boston Scientific$709
  • Takeda Pharmaceuticals U.S.A., Inc.$549
  • Endogastric Solutions, Inc$402
  • plus $2K from 25 others

What the payments were for

  • Consulting fees$120%
  • Speaking & faculty fees$30,44074%
  • Travel & lodging$1,5004%
  • Food & beverage$9,14522%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,109 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$96,636
Medicare patients
335
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide27$21,685
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates55$3,713
Dexlansoprazole DrDexlansoprazole12$2,569
Ursodiol15$960
Pantoprazole Sodium43$379
Omeprazole41$329
Spironolactone11$146
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$14,164$21,68527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Florence

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →